2-Methyl-2-(2,2,2-trifluoroethoxy)propane | 80054-67-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Methyl-2-(2,2,2-trifluoroethoxy)propane
• CAS: 80054-67-7
• 化学式: C₆H₁₁F₃O
• 分子量: 156.148
• InChiKey: GSYUWIACDWCNCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-isobutyl-N-nitro-O-benzoylhydroxylamine 以 水 为溶剂， 生成 2-Methyl-2-(2,2,2-trifluoroethoxy)propane 、 叔丁醇
  参考文献：
  名称：

  Synthesis and decomposition of the N-alkyl-N-nitro-O-benzoylhydroxylamines

  摘要：

  DOI：

  10.1021/jo00199a025

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130183269A1

  公开（公告）日：2013-07-18

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白功能的化合物组合，包括这种组合的组成物，以及抑制NS5A蛋白功能的方法。
• BACE INHIBITORS
  申请人：Eli Lilly and Company

  公开号：US20140371212A1

  公开（公告）日：2014-12-18

  The present invention provides a compound of Formula III: wherein A is: and Z, R 1 , R 2 , R 3 , and R 4 are as defined herein, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种III式化合物：其中A是：以及Z、R1、R2、R3和R4如本文所定义，或其药学上可接受的盐。
• Fused Heterocyclic Compounds as Ion Channel Modulators
  申请人：Kobayashi Tetsuya

  公开号：US20120010192A1

  公开（公告）日：2012-01-12

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类是钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该类化合物的结构由式I给出：其中R1、R2、R3、R4和R5如本文所述，以及制备和使用该类化合物的方法，以及含有这些化合物的药物组合物。
• AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING
  申请人：Tso Kin

  公开号：US20180111917A1

  公开（公告）日：2018-04-26

  Disclosed embodiments concern novel interleukin receptor associated kinases (IRAK) inhibitors and compositions comprising such inhibitors. Also disclosed are methods of making and using the compounds and compositions. The disclosed compounds and/or compositions may be used to treat or prevent an IRAK-associated disease or condition.

  揭示的实施例涉及新型白细胞介素受体相关激酶（IRAK）抑制剂和包含此类抑制剂的组合物。还揭示了制备和使用这些化合物和组合物的方法。所揭示的化合物和/或组合物可用于治疗或预防与IRAK相关的疾病或症状。
• IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS
  申请人：BIOGEN MA INC.

  公开号：US20220089592A1

  公开（公告）日：2022-03-24

  This invention relates to Imidazo[1,2-a]pyridinyl Derivatives of formula (I′), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The invention further provides a method of manufacturing compounds of the invention, and methods for their therapeutic use. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including inflammatory disease, autoimmune disease, cancer, cardiovascular disease, a disease of the central nervous system, disease of the skin, an ophthalmic disease and condition, and a bone disease.

  这项发明涉及Imidazo[1,2-a]pyridinyl Derivatives的化合物（I′）或其药学上可接受的盐，其中所有变量如规范中所定义，能够调节IRAK4的活性。该发明进一步提供了一种制造该发明化合物的方法，以及它们在治疗中的方法。该发明还提供了它们的制备方法，医学用途，特别是在治疗和管理炎症性疾病、自身免疫疾病、癌症、心血管疾病、中枢神经系统疾病、皮肤疾病、眼科疾病和骨骼疾病等疾病或疾病的用途。